Featured Research

from universities, journals, and other organizations

Effect Of Race In Prostate Cancer Survival Is Questioned

Date:
May 21, 2002
Source:
Dana-Farber Cancer Institute
Summary:
African-American patients with advanced prostate cancer survived slightly longer than white patients, according to a multi-institutional study led by Dana-Farber Cancer Institute researchers. The findings, which run counter to the conventional notion that African-Americans with the disease die sooner, were presented at the annual meeting of the American Society of Clinical Oncology in Orlando on May 19.

ORLANDO -- African-American patients with advanced prostate cancer survived slightly longer than white patients, according to a multi-institutional study led by Dana-Farber Cancer Institute researchers. The findings, which run counter to the conventional notion that African-Americans with the disease die sooner, were presented at the annual meeting of the American Society of Clinical Oncology in Orlando on May 19.

The data were derived from a pooled analysis of four randomized clinical trials in men with advanced prostate cancer that was no longer being held in check by hormone treatments. On average, African-Americans in the trials survived a median of 15 months while for whites the median survival was 14 months.

"This is evidence that African-Americans do just as well as whites when they're treated within the context of a clinical trial," said Timothy D. Gilligan, MD, a genitourinary oncologist at Dana-Farber. "This should discourage a pessimistic approach to prostate cancer in African-Americans in this setting."

The finding, said Gilligan, contradicts epidemiological evidence that has suggested that prostate cancer is more aggressive in African-Americans than in white men. Studies have shown that African-Americans typically are diagnosed with more advanced prostate cancer and that when treated, they have a higher mortality rate than whites do. But Gilligan said differences in treatment could explain the discrepancy.

The researchers, who include investigators from Dana-Farber, Duke University, the University of Maryland, the University of California at San Francisco, and the University of Chicago, pooled the outcomes of four trials of several different treatments for hormone-refractory prostate cancer. There were 844 white and 144 African-American men in the studies. Their average age was 71, and 90 percent had metastases to other organs.

Gilligan noted that it's not possible to generalize from this study to all prostate cancer patients: this was a select group of patients with the most advanced form of the disease. This slight survival advantage for African-Americans, however, should prompt further studies, said Gilligan, and it should help attract more African-Americans into prostate cancer trials.

Dana-Farber Cancer Institute (http://www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Effect Of Race In Prostate Cancer Survival Is Questioned." ScienceDaily. ScienceDaily, 21 May 2002. <www.sciencedaily.com/releases/2002/05/020521071410.htm>.
Dana-Farber Cancer Institute. (2002, May 21). Effect Of Race In Prostate Cancer Survival Is Questioned. ScienceDaily. Retrieved September 15, 2014 from www.sciencedaily.com/releases/2002/05/020521071410.htm
Dana-Farber Cancer Institute. "Effect Of Race In Prostate Cancer Survival Is Questioned." ScienceDaily. www.sciencedaily.com/releases/2002/05/020521071410.htm (accessed September 15, 2014).

Share This



More Health & Medicine News

Monday, September 15, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins